CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-125906 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Clinical Oncology Next Generation Sequencing Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET

7.1 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Illumina, Inc.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 F. Hoffmann-La Roche Ltd

16.3 Agilent Technologies

16.4 Thermo Fisher Scientific Inc.

16.5 Myriad Genetics, Inc.

16.6 Beijing Genomics Institute (BGI)

16.7 Qiagen NV

16.8 Perkin Elmer, Inc.

16.9 Pacific Bioscience, Inc.

16.10 Partek, Inc.

16.11 Foundation Medicine Inc.

16.12 Oxford Nanopore Technologies Ltd.

16.13 Paradigm Diagnostics, Inc

16.14 Caris Life Sciences

16.15 Eurofins Scientific S.E.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Technology
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing

By Workflow
NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis

By Application
Screening
 o Sporadic Cancer
 o Inherited Cancer
Companion Diagnostics
Others

By End User
Hospitals
Clinics
Laboratories

Competitive Landscape:
Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:
Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:
To provide with an exhaustive analysis on the Clinical Oncology Next Generation Sequencing Market By Technology, By Workflow, By Application, By End User and

Companies

Illumina, Inc.
F. Hoffmann-La Roche Ltd
Agilent Technologies
Thermo Fisher Scientific Inc.
Myriad Genetics, Inc.
Beijing Genomics Institute (BGI)
Qiagen NV
Perkin Elmer, Inc.
Pacific Bioscience, Inc.
Partek, Inc.
Foundation Medicine Inc.
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics, Inc
Caris Life Sciences
Eurofins Scientific S.E.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.